Kura Oncology, Inc. (KURA) Income Statement
KURA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsKURA revenue and net income
Where KURA's revenue goes
2025Each bar shows an amount and its share of revenue. KURA kept −412.9% of revenue as net income.
KURA profit margins
KURA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +25.2% | — | — | — |
| Gross profit | +25.1% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
KURA quarterly EPS vs estimates
Kura Oncology beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.83).
KURA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $57,000 | $848,000 | $849,000 | $759,000 | $558,000 | $194,000 | — | $10,000 | $30,000 | $31,000 |
| Gross profit | $67.4M | $53.9M | −$849,000 | −$759,000 | −$558,000 | −$194,000 | — | −$10,000 | −$30,000 | −$31,000 |
| Research & development | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M | $60.4M | $47.8M | $46.8M | $26.4M | $20.4M |
| Sales, general & admin | $120.0M | $77.1M | $51.4M | $47.1M | $46.5M | $31.3M | $19.7M | $16.1M | $9.7M | $8.0M |
| Total operating expenses | $371.1M | $247.1M | $165.0M | $139.9M | $131.3M | $91.7M | $67.5M | $62.9M | $36.1M | $28.4M |
| Operating income | −$303.6M | −$193.2M | −$165.8M | −$139.9M | −$131.3M | −$91.9M | −$67.5M | −$62.9M | −$36.1M | −$28.4M |
| Interest income | $26.8M | $22.8M | $12.6M | $4.3M | $1.2M | $2.8M | $4.7M | $3.2M | $751,000 | $499,000 |
| Interest expense | $1.5M | $1.6M | $1.5M | $229,000 | $414,000 | $578,000 | $580,000 | $970,000 | $888,000 | $577,000 |
| Income before taxes | −$278.4M | −$172.0M | −$152.6M | −$135.8M | −$130.5M | −$89.6M | −$63.1M | −$60.4M | −$35.4M | −$27.6M |
| Income taxes | $297,000 | $2.0M | — | $229,000 | −$558,000 | −$194,000 | −$4.9M | $3.4M | −$30,000 | −$31,000 |
| Net income | −$278.7M | −$174.0M | −$152.6M | −$135.8M | −$130.5M | −$89.6M | −$63.1M | −$60.4M | −$35.4M | −$27.6M |
| EBITDA | −$275.8M | −$169.5M | −$150.2M | −$134.9M | −$129.5M | −$88.9M | −$67.5M | −$62.9M | −$36.0M | −$28.3M |
| EPS (diluted) | −$3.18 | −$2.03 | −$2.08 | −$2.03 | −$1.96 | −$1.69 | −$1.50 | −$1.73 | −$1.54 | −$1.47 |
| Gross margin | 99.9% | 100.0% | — | — | — | — | — | — | — | — |
| Operating margin | −449.9% | −358.5% | — | — | — | — | — | — | — | — |
| Net margin | −412.9% | −322.9% | — | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9M | $18.3M | $17.3M | $20.8M | $15.3M | $14.1M | $53.9M | $0 | $0 | $0 | $1.3M | $0 |
| Cost of revenue | $243,000 | $617,000 | $460,000 | $3.2M | $224,000 | $0 | $204,000 | $208,000 | $202,000 | $234,000 | $214,000 | $216,000 |
| Gross profit | $20.6M | $17.6M | $17.3M | $17.5M | $15.3M | $14.1M | $53.9M | −$208,000 | −$202,000 | −$234,000 | −$214,000 | −$216,000 |
| Research & development | $61.9M | $65.3M | $64.4M | $67.9M | $62.8M | $56.0M | $52.3M | $41.7M | $39.7M | $36.3M | $32.5M | $29.3M |
| Sales, general & admin | $31.8M | $31.6M | $39.1M | $32.8M | $25.2M | $22.8M | $24.1M | $18.2M | $16.9M | $18.4M | $14.4M | $13.1M |
| Total operating expenses | $93.6M | $96.5M | $103.6M | $97.5M | $88.0M | $78.8M | $76.3M | $59.9M | $56.2M | $54.2M | $46.5M | $42.3M |
| Operating income | −$73.0M | −$78.8M | −$86.3M | −$80.0M | −$72.7M | −$64.7M | −$22.5M | −$59.9M | −$56.4M | −$54.5M | −$46.8M | −$42.5M |
| Interest income | $5.0M | $5.8M | $5.7M | $6.3M | $6.9M | $7.9M | $5.7M | $5.9M | $6.0M | $5.3M | $4.4M | $4.3M |
| Interest expense | $345,000 | $336,000 | $346,000 | $393,000 | $391,000 | $382,000 | $403,000 | $412,000 | $406,000 | $398,000 | $394,000 | $404,000 |
| Income before taxes | −$68.3M | −$73.3M | −$80.9M | −$74.1M | −$66.1M | −$57.2M | −$17.2M | −$54.4M | −$50.8M | −$49.5M | −$42.8M | −$38.6M |
| Income taxes | $5,000 | $8,000 | $71,000 | — | — | $226,000 | $2.0M | — | — | $190,724 | $2.9M | $404,000 |
| Net income | −$68.3M | −$73.3M | −$81.0M | −$74.1M | −$66.1M | −$57.4M | −$19.2M | −$54.4M | −$50.8M | −$49.5M | −$42.8M | −$38.6M |
| EBITDA | −$67.6M | −$72.6M | −$80.2M | −$74.0M | −$65.5M | −$57.3M | −$16.6M | −$53.8M | −$50.2M | −$48.9M | −$42.2M | −$38.0M |
| EPS (diluted) | −$0.77 | −$0.83 | −$0.92 | −$0.85 | −$0.75 | −$0.66 | −$0.22 | −$0.63 | −$0.59 | −$0.59 | −$0.55 | −$0.50 |
| Gross margin | 98.8% | 96.6% | 100.0% | 84.5% | 100.0% | 100.0% | 100.0% | — | — | — | −16.9% | — |
| Operating margin | −349.8% | −431.5% | −497.6% | −385.5% | −475.3% | −458.6% | −41.7% | — | — | — | −3,682.0% | — |
| Net margin | −327.3% | −401.5% | −467.2% | −357.2% | −432.5% | −407.1% | −35.7% | — | — | — | −3,369.0% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in KURA's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
KURA financial results
In fiscal year 2025 (ended December 31, 2025), Kura Oncology reported revenue of $67.5 million, up 25.2% from the year before. It had a net loss of $278.7 million, a net profit margin of −412.9%. Diluted earnings per share came to −$3.18.
See the KURA stock overview for the latest quote and news, or the KURA chart for price history and technical indicators.
KURA income statement FAQ
What is Kura Oncology's annual revenue?
Kura Oncology reported total revenue of $67.5 million for fiscal year 2025, which ended on December 31, 2025. That was up 25.2% from $53.9 million the previous year.
Is Kura Oncology profitable?
No. Kura Oncology reported a net loss of $278.7 million in fiscal 2025, a net profit margin of −412.9%; its operating margin was −449.9%.
What is Kura Oncology's gross margin?
Kura Oncology's gross margin was 99.9% in fiscal 2025: for every $100 of revenue, Kura Oncology kept $100 after the direct cost of its products and services.
How much does Kura Oncology spend on research and development?
Kura Oncology spent $251.1 million on research and development in fiscal 2025, 372.1% of revenue.
What are Kura Oncology's earnings per share?
Kura Oncology earned $-3.18 per diluted share in fiscal 2025, compared with $-2.03 a year earlier.
When will Kura Oncology report its next earnings?
Kura Oncology is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Kura Oncology's fiscal year end?
Kura Oncology's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.